Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD-Reference-Cited by-同舟云学术

Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD

Published:2013-05-03 Issue:4 Volume:15 Page:439-445
ISSN:1618-7598
Container-title:The European Journal of Health Economics
language:en
Short-container-title:Eur J Health Econ

Author:

Camejo Rodrigo Refoios,McGrath Clare,Miraldo Marisa,Rutten Frans

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Economics, Econometrics and Finance (miscellaneous)

Link

http://link.springer.com/content/pdf/10.1007/s10198-013-0484-1.pdf

Reference24 articles.

1. Grabner, M., et al.: The value of atorvastatin over the product life cycle in the United States. Clin. Ther. 33(10), 1433–1443 (2011)

2. Garthwaite, C.: The economic benefits of pharmaceutical innovations: the case of cox-2 inhibitors. Am. Econ. J. Appl. Econ. 4(3), 116–137 (2012)

3. Cutler, D., et al.: The value of antihypertensive drugs: a perspective on medical innovation. Health Aff. 26(1), 97–110 (2007)

4. Goldman, D., et al.: The value of specialty oncology drugs. Health Serv. Res. 45(1), 115–132 (2010)

5. Jena, A., Philipson, T.: Cost-effectiveness as a price control. Health Aff. 26(3), 696–703 (2007)

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Considering Returns on Federal Investment in the Negotiated “Maximum Fair Price” of Drugs Under the Inflation Reduction Act: an Analysis;2024-02-28

2. The Allocation of the Economic Value of Second-Generation Antipsychotics Over the Product Life Cycle: The Case of Risperidone in Sweden and the United Kingdom;Value in Health;2023-03

3. Decision Criteria for Partial Nationalization of Pharmaceutical Supply Chain: A Scoping Review;Economies;2023-01-12

4. Estimating the shares of the value of branded pharmaceuticals accruing to manufacturers and to patients served by health systems;Health Economics;2021-08-02

5. Erratum to: Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD;The European Journal of Health Economics;2013-06-18